AKT1 and lung carcinoma: These results confirm previous experiments on lung cancer (Sun and Sun, 2019) and hepatocellular carcinoma cells (Zhang et al., 2020) showing an inhibitor effect of lidocaine on PI3K/AKT/mTORC1 pathway, evidenced by assessing the phosphorylation levels of PI3K and AKT by western blot.